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Abstract 
Background: A pre‑specified meta‑analysis of cardiovascular (CV) events from 21 phase 2b/3 dapagliflozin clinical 
trials was undertaken to characterise the CV profile of dapagliflozin. This showed no increase in CV risk with dapa‑
gliflozin compared with control (placebo or comparator treatment) with or without background glucose‑lowering 
therapies. The analysis reported here aimed to characterise the CV profile of dapagliflozin in subgroups of patients in 
these 21 studies grouped by degree of CV risk, based on both baseline and in‑study risk factors (including hypogly‑
caemic events), with a focus on major adverse CV events (MACE).
Methods: Patients with type 2 diabetes, both overall and with different levels of CV risk, including CV disease (CVD) 
history, age and other CV risk factors, were analysed. A further analysis compared CV risk in patients who experienced 
a hypoglycaemic event prior to MACE and those who did not. Analyses were based on time to first event using a Cox 
proportional hazards model stratified by study comparing dapagliflozin versus control.
Results: In total, 9339 patients were included in this meta‑analysis; 5936 patients received dapagliflozin 2.5–10 mg 
(6668 patient–years) and 3403 received control (3882 patient–years). Dapagliflozin is not associated with increased CV 
risk and results further suggest the potential for a beneficial effect both in the overall population [Hazard Ratio (HR) 
0.77; 95 % CI (0.54, 1.10) for MACE] and in those with a history of CVD [HR 0.80 (0.53, 1.22)]. These findings were con‑
sistent in patients with varying degrees of CV risk, including age, number and type of CVD events in medical history 
and number of CV risk factors present. Furthermore, there was no increased risk of MACE in patients who experienced 
a hypoglycaemic event compared with those who did not.
Conclusions: There was no suggestion of increased risk for MACE with dapagliflozin compared with control in 
any of the populations investigated. In addition, the results suggest the potential for a beneficial CV effect which is 
consistent with the multifactorial benefits on CV risk factors associated with sodium–glucose cotransporter‑2 (SGLT2) 
inhibitors.
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Background
In patients with type 2 diabetes mellitus (T2DM), car-
diovascular disease (CVD) remains the leading cause 
of morbidity and mortality, with these individuals at 
approximately twice the risk of CVD compared with 
people without diabetes [1, 2]. Although rates have 
declined, a large burden still remains [3].
The link between improved glycaemic control and an 
improvement in microvascular outcomes is well estab-
lished; however, although epidemiological evidence sug-
gests a link [4–6], the effect on CVD risk is less clear 
[7–11]. In addition, the potential harm associated with 
severe hypoglycaemia might counterbalance the potential 
benefit of intensive glucose lowering treatment [12]. The 
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need for personalised treatment of hyperglycaemia has 
been advocated [13–15] and a multifactorial approach 
to the treatment of risk factors is needed to decrease the 
cardiovascular (CV) risk [16, 17].
Dapagliflozin is a selective sodium–glucose cotrans-
porter-2 (SGLT2) inhibitor that lowers blood glucose 
levels by reducing glucose reabsorption in the kidney 
independently of insulin secretion or action, resulting 
in increased urinary glucose excretion with associated 
osmotic diuresis and caloric loss [18]. The efficacy and 
safety of dapagliflozin has been studied in a wide range 
of populations as monotherapy or in combination with a 
variety of other glucose-lowering therapies [19–38]. The 
mechanism of action of dapagliflozin influences a num-
ber of CVD risk factors, in particular, decreasing blood 
pressure, reducing body weight (predominantly through 
reductions in total body fat mass, including visceral adi-
pose tissue), reducing waist circumference, and lowering 
albuminuria and serum uric acid levels, with a low intrin-
sic risk of hypoglycaemia [26, 39, 40].
The US Food and Drug Administration (FDA) and 
European Medicines Agency (EMA) have issued guid-
ance requiring that new diabetes therapies should rule 
out an unacceptable increase in CVD risk [41, 42]. Since 
then, a number of large CV outcome studies to clarify the 
effects of new classes of glucose-lowering therapies have 
either been conducted [43–47] or are ongoing [48–50]. 
Positive CV outcomes data, including a beneficial effect 
on hospitalisation for heart failure, were recently pub-
lished for the SGLT2 inhibitor empagliflozin, which has 
a similar profile to dapagliflozin, showing the benefits of 
improving multiple CV risk factors with SGLT2 inhibi-
tors [47]. Additionally, the ongoing large CV outcome 
trial DECLARE TIMI-58 [48] is being conducted in a 
broad population of patients with either established CVD 
or multiple CV risk factors and will aim to evaluate the 
effects of dapagliflozin on CV outcomes, with an esti-
mated completion date of 2019.
In a pre-specified meta-analysis investigating CV out-
comes in 21 trials from the dapagliflozin clinical develop-
ment programme, which was conducted in line with the 
FDA guidance, no increase in CVD risk was observed in 
patients with T2DM receiving dapagliflozin compared 
with those receiving control (placebo or comparator 
treatment) with or without background glucose-lower-
ing therapies [51]. The CV risk increases in patients with 
age, decrease in renal function and presence of one or 
several risk factors or comorbid conditions. The meta-
analysis reported here aimed to characterise the CV pro-
file of dapagliflozin overall and in subgroups of patients 
grouped by degree of CV risk, based both on baseline 
and in-study risk factors (i.e. hypoglycaemic events), with 
a focus on major adverse CV events (MACE).
Methods
Patient population
Data from Phase 2b studies of 12–24  weeks’ duration 
(five studies), and all Phase 3 studies of up to 208 weeks’ 
duration (16 studies) from the dapagliflozin clinical 
development programme in patients with T2DM, with 
the exception of an open-label Japanese study, were 
included (Additional file 1: Table S1). These studies com-
pared dapagliflozin 2.5–10  mg with control (placebo or 
comparator treatment) as monotherapy or in combina-
tion with other glucose-lowering therapies, including 
metformin, sulfonylureas, thiazolidinediones, insulin 
and dipeptidyl peptidase 4 inhibitors. Methods for each 
individual study have previously been published [19–38]. 
All clinical study protocols were approved by the relevant 
institutional review boards/ethics committees and all 
enrolled patients provided written informed consent.
Analyses of CV outcomes were performed in several 
populations:
  • In the overall population, comparison of CV outcomes 
according to the number of CV risk factors present 
in addition to T2DM. Cardiovascular risk factors 
included: age >65  years, history of CVD, history of 
hypertension, history of dyslipidaemia, smoking his-
tory, first degree family members with a history of pre-
mature coronary heart disease, and baseline estimated 
glomerular filtration rate (eGFR) <60 mL/min/1.73 m2.
  • In a subpopulation with a history of CVD:
•  Comparison of CV outcomes according to the 
types of previous CVD events experienced and 
the number of different CVD event types in a 
patient’s history. The types of previous CVD 
events were defined as: coronary artery disease 
(myocardial infarction [MI], hospitalisation for 
unstable angina [UA], coronary artery bypass 
graft, percutaneous coronary intervention or 
stable angina), cerebrovascular disease (carotid 
artery disease, carotid endarterectomy or 
stenting, stroke or transient ischaemic attack), 
peripheral vascular disease (amputation, periph-
eral vascular disease or peripheral vascular sur-
gery) or congestive heart failure (CHF).
  • In a subpopulation of elderly patients aged ≥65 years 
with a history of both CVD and hypertension.
  • Comparison of patients with or without hypoglycae-
mia prior to MACE in both the overall population 
and the subpopulation of patients with a history of 
CVD.
Cardiovascular outcomes
Cardiovascular safety events were identified through 
an independent, blinded adjudication process, with 
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standardised MedDRA (Medical Dictionary for Regula-
tory Activities) queries used to select the events for adju-
dication. In line with the FDA Guidance, the primary 
CVD event of interest in this meta-analysis was the com-
posite of CVD death, MI, stroke and hospitalisation for 
UA (MACE plus UA) although we focus on MACE (com-
posite of CVD death, MI and stroke) for the majority of 
the analyses here. Other CVD events investigated were 
the individual events of CV death, MI, stroke, hospitali-
sation for UA, unplanned coronary revascularisation, and 
hospitalisation for heart failure.
Analysis methods
Analyses were based on time to first event using a Cox 
proportional hazards model stratified by study and 
including a term defining the treatment received by 
individual patients across the pooled studies (either 
dapagliflozin or control). Results were supported by 
Mantel–Haenszel methods (asymptotic and exact). Only 
studies with at least one adjudicated event contributed to 
the respective analyses. Any imbalances in CVD risk fac-
tors due to an unequal randomisation ratio were adjusted 
for in the analyses through stratification by study in the 
model. Hazard ratios (HRs) and 95 % confidence intervals 
(CIs) comparing dapagliflozin with control were calcu-
lated. An estimated HR <1 indicates a favourable effect of 
dapagliflozin versus control. Kaplan–Meier estimates for 
cumulative incidence were calculated for MACE + UA, 
MACE, their individual components (CV death, MI, 
stroke and UA) and hospitalisation for heart failure.
Results
Patients
Overall there were 9339 patients included in this meta-
analysis, with 10,550 patient–years of exposure to study 
drug; 5936 patients received dapagliflozin (6668 patient–
years) and 3403 received control (3882 patient–years). 
There were 3214 patients with a history of CVD (1856 
and 1358 treated with dapagliflozin and control, respec-
tively); the subgroup of elderly patients (≥65  years) 
with a history of CVD and hypertension included 1263 
patients from 19 studies (707 patients treated with dapa-
gliflozin and 556 with control). Patient demograph-
ics and baseline characteristics were balanced between 
dapagliflozin and control groups within each studied 
population (Table  1). Patients with history of CVD, 
and elderly patients with history of CVD and hyperten-
sion, were older, had a longer T2DM duration, more 
impaired renal function, lower low-density lipoprotein 
(LDL)-cholesterol and higher mean systolic blood pres-
sure, compared with patients in the overall population. 
In the overall population, a slight imbalance in history of 
CVD, hypertension and CHF between dapagliflozin and 
control groups was observed and this was accounted for 
in the analysis.
Cardiovascular outcomes in the overall population
A total of 176 MACE plus UA events were observed 
in the overall population; 95 events in patients receiv-
ing dapagliflozin and 81 events in patients receiving 
control [HR 0.787; 95  % CI (0.579, 1.070)] (Fig.  1). A 
total of 134 MACE events (72 events in patients receiv-
ing dapagliflozin and 62 events in patients receiving 
control) were observed in the overall population [HR 
0.772; 95  % CI (0.543, 1.097)] (Fig.  1). The cumulative 
probability of MACE  +  UA and MACE both showed 
a gradual separation of the dapagliflozin and con-
trol curves during the treatment period (Fig. 2). There 
was a consistent pattern, with beneficial or neutral 
point estimates for all individual types of CV events in 
dapagliflozin- compared with control-treated patients 
(Fig. 3), including a beneficial estimate on hospitalisa-
tion for heart failure [HR 0.361; 95 % CI (0.156, 0.838)] 
(Fig. 3), which showed an early separation of the cumu-
lative probability of an event between the treatment 
groups (Fig.  2); albeit only based on 26 events. For all 
Kaplan–Meier plots in Fig. 2, the relatively few events 
occurring in the later time period should be noted. 
The presence or absence of specific CVD risk factors 
(including family history of premature coronary heart 
disease, baseline eGFR, dyslipidaemia, hypertension, 
smoking, history of CVD and older age), did not gen-
erally affect the estimated HRs, which were less than 1 
in all subgroups analysed (Fig. 4). When patients were 
considered according to the present number of CVD 
risk factors, estimated HRs were less than 1 for all cat-
egories (≥1, ≥2, ≥3, ≥4, ≥5 or ≥6 risk factors) with a 
tendency towards higher event rates with increasing 
number of risk factors in both the dapagliflozin and the 
control groups (Fig. 5).    
Cardiovascular outcomes in patients with a history of CVD
A total of 128 MACE plus UA events were observed 
in the subgroup of patients with a history of CVD; 67 
events in patients receiving dapagliflozin and 61 events 
in patients receiving control [HR 0.806; 95  % CI (0.562, 
1.156)] (Fig. 1). A total of 95 MACE events were observed 
in this subgroup; 50 in patients receiving dapagliflozin 
and 45 in patients receiving control [HR 0.802; 95 % CI 
(0.527, 1.221)] (Fig.  1). The risk for MACE events with 
dapagliflozin compared with control in patients without 
a history of CVD also favoured dapagliflozin [HR 0.646; 
95 % (0.336, 1.241)] (Fig. 4). The pattern of beneficial or 
neutral point estimates for all individual types of CV 
events in dapagliflozin- compared with control-treated 
patients and a beneficial point estimate for dapagliflozin 
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versus control for hospitalisation for heart failure, was 
also seen in this population (Fig.  3). This was also true 
for MI, where similar results were observed in the over-
all population and patients with a history of CVD, albeit 
with fewer events in the latter population.
When patients were considered according to types of 
CVD history (Fig. 6a) or number of distinct CVD types 
experienced in their history (according to the same 
classes; Fig. 6b), there was no increase in risk for MACE 
in patients treated with dapagliflozin compared with 
those treated with control.
Cardiovascular outcomes in elderly patients with a history 
of CVD and hypertension
In the subgroup of elderly patients aged at least 65 years 
who had a history of CVD and hypertension, a total of 
65 MACE plus UA events were observed (33 in patients 
receiving dapagliflozin and 32 in patients receiving con-
trol) [HR 0.824; 95  % CI (0.497, 1.365)] (Fig.  1), and a 
total of 49 MACE events were observed (26 in patients 
receiving dapagliflozin and 23 in patients receiving con-
trol) [HR 0.916; 95  % CI (0.512, 1.640)]. There was no 
increase in risk for any of the individual components of 
MACE in dapagliflozin-treated patients compared with 
those receiving control, although the number of events 
was low for each individual endpoint (Fig. 3).
Cardiovascular outcomes in patients with or 
without hypoglycaemia prior to MACE
No increased risk for MACE was observed with dapa-
gliflozin compared with control in patients who did or 
did not experience a hypoglycaemic event prior to a first 
MACE event. This was consistently observed in both 
the overall population and the subpopulation of patients 
Table 1 Demographics and baseline characteristics
ACEi angiotensin converting enzyme inhibitors, ARBS angiotensin receptor blockers, BMI body mass index, CHF congestive heart failure, CTRL control, CVD 
cardiovascular disease, DAPA dapagliflozin, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, LDL low density lipoprotein cholesterol, SD 
standard deviation, SBP systolic blood pressure
a Two patients were not randomised to dapagliflozin, but were subsequently treated with dapagliflozin; b Other includes Black or African American, Asian and 
Other; c n = 3400; d n = 3402; e n = 1357; f n = 5742; g n = 3234; h n = 1821; i n = 1316; j n = 698; k n = 543; l n = 5619; m n = 3274; n n = 1824; o n = 1345; p n = 704; 
q n = 553
All patients Patients with history of CVD Elderly patients with hyper-













Age, mean (SD), years 56.9 (10.4) 58.1 (10.3) 62.4 62.9 70.2 (4.1) 70.1 (4.2)
  ≥65 years (%) 24.0 28.8 40.9 43.1 100 100
Race
  White, n (%) 4505 (75.9) 2644 (77.7) 1634 (88.0) 1199 (88.3) 634 (89.7) 521 (93.7)
  Otherb, n (%) 1431 (24.1) 759 (22.3) 222 (12.0) 159 (11.7) 73 (10.3) 35 (6.3)
BMI, mean (SD), kg/m2 31.3 (5.7) 31.6 (5.8) 32.4 (5.4) 32.5 (5.9) 31.8 (5.0) 32.1 (5.4)
T2DM duration, mean (SD), years 7.0 (7.5) 7.6 (7.7)c 11.1 (8.4) 11.2 (8.3) 13.4 (9.3) 13.0 (9.1)
History of CVD (%) 31.3 39.9 100 100 100 100
History of hypertension (%) 65.7 71.9 89.8 92.8 100 100
History of CHF (%) 3.9 4.8 12.6 12.0 15.4 15.3
Smoking history (%) 43.3 46.3 53.3 56.4 51.8 53.1
eGFR, mean (SD), mL/min/1.73 m2 83.9 (21.3) 83.6 (21.1)d 75.7 (19.5) 77.0 (19.5)e 69.9 (18.5) 71.7 (17.9)
LDL, mean (SD), mmol/L 2.78 (0.98)f 2.66 (0.96)g 2.47 (0.98)h 2.36 (0.92)i 2.32 (0.90)j 2.28 (0.89)k
SBP, mean (SD), mmHg 130.4 (15.7)l 131.1 (14.9)m 134.5 (15.4)n 133.7 (14.5)o 136.7 (15.7)p 135.6 (14.0)q
DBP, mean (SD), mmHg 78.8 (9.1)l 78.8 (8.9)m 78.0 (9.3)n 77.7 (9.1)o 76.1 (9.3)p 76.1 (9.0)q
Concomitant medications of interest:
   Any antihypertensive 3217 (54.2) 2061 (60.6) 1440 (86.4) 1085 (86.1) 604 (85.4) 476 (85.6)
   Diuretics 1509 (25.4) 960 (28.2) 788 (47.3) 604 (47.9) 363 (51.3) 282 (50.7)
   β‑blockers 1604 (27.0) 1127 (33.1) 1045 (62.7) 819 (65.0) 454 (64.2) 367 (66.0)
   ACEi/ARBs 2938 (49.5) 1908 (56.1) 1327 (79.7) 1022 (81.1) 556 (78.6) 451 (81.1)
   Calcium channel blockers 1126 (19.0) 717 (21.1) 545 (32.7) 431 (34.2) 251 (35.5) 203 (36.5)
 Statins 2276 (38.3) 1582 (46.5) 1145 (68.7) 928 (73.7) 497 (70.3) 408 (73.4)
 Aspirin 1906 (32.1) 1322 (38.8) 1068 (64.1) 858 (68.1) 456 (64.5) 378 (68.0)
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with a history of CVD (Fig.  7). The MACE event rates 
observed were not consistently higher in patients with a 
hypoglycaemic event, rather the opposite, although the 
comparison is hampered by both types of events being 
post-randomisation events.
Discussion
To carefully characterise the properties of dapagliflozin, 
the meta-analysis described here included a broad popu-
lation of patients with a particular focus on those with an 
elevated risk for CV events, using different subpopula-
tions of varying risk. The point estimates of the HRs for 
MACE and MACE plus UA were similar and in favour of 
dapagliflozin in the overall population as well as for the 
sub-populations with higher CV risk. Glycaemic variabil-
ity and episodes of severe hypoglycaemia have been sug-
gested as predictors of adverse CV outcomes in patients 
with T2DM [7, 52–58]. Dapagliflozin reduces hypergly-
caemia independently of insulin secretion or action, and 
as such, has a low intrinsic propensity for hypoglycaemia. 
In our analysis there was no increased risk for MACE 
in patients treated with dapagliflozin who did or did 
not experience a hypoglycaemic event prior to the first 
MACE event, although the number of events was small.
The results reported here are consistent with previously 
published meta-analyses of the effect of SGLT2 inhibitors 
on CV events. One analysis included pooled data from 
clinical trials of several members of the SGLT2 inhibi-
tor class, evaluating MACE plus UA in 17,180 patients 
from 25 studies (14 dapagliflozin, one empagliflozin and 
10 canagliflozin studies) [59]. This analysis found no evi-
dence for increased CV risk, with the HR point estimate 
in favour of the SGLT2 inhibitor [HR 0.89; 95 % CI (0.70, 
1.14)] [59]. Meta-analysis provides a method for aggre-
gating and interpreting data from multiple sources and 
is, therefore, an important tool for examining rare CV 
events that occur in diabetes clinical trials [60]. Although 
CV events here were prospectively adjudicated by an 
independent committee, one should note the limitations 
in the heterogeneous nature of the study populations, the 
post hoc nature of some of the analyses, the relatively low 
numbers of events and that data are not generated in a 
prospectively designed CV outcomes trial.
In addition to reducing hyperglycaemia in T2DM, dapa-
gliflozin may improve glycaemic control in patients with 
T1DM [61]. Furthermore, dapagliflozin is known to have 
beneficial effects on several important CV risk factors, and 































33/653 32/535 Elderly patients with CVD risk )563.1,794.0(428.060.591.4
)046.1,215.0(619.0535/32356/62Elderly patients with CVD risk 3.28 3.61 
0111.0
Subgroup 
Fig. 1 MACE + UA and MACE. Data presented for the overall population, the subgroup of patients with a history of CVD (CVD history) and the 
subgroup of elderly patients aged ≥65 years with a history of CVD and hypertension (Elderly patients with CVD risk). n is the number of patients 
with an event; N is the number of patients in treatment group. CI confidence interval, CTRL control, CVD cardiovascular disease, DAPA dapagliflozin, 
HR hazard ratio, MACE major adverse cardiovascular events (cardiovascular death, myocardial infarction and stroke), MACE + UA MACE plus unstable 
angina, p–y = patient years
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hypertension and T2DM have reported clinically mean-
ingful improvements in blood pressure, body weight, and 
serum uric acid levels with dapagliflozin [62, 63]. Dapa-
gliflozin is also associated with beneficial effects on albu-
minuria [64, 65]; collectively suggesting a favourable CV 
profile. It has also been postulated that the mechanisms 
underlying the CV benefits of SGLT2 inhibitors could be 
even more multidimensional and may involve changes in 
arterial stiffness, cardiac oxygen demand, oxidative stress 
as well as other potential effects on the sympathetic nerv-
ous system, ventricular function and remodelling that 
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g Hospitalisation for heart failure
Fig. 2 Cumulative incidence of a MACE + UA, b MACE, c CV death, d MI, e stroke, f UA and g hospitalisation for heart failure (Kaplan–Meier esti‑
mates). Data presented for the overall population. CV cardiovascular, DAPA dapagliflozin, MACE major adverse cardiovascular events (CV death, MI 
and stroke), MI myocardial infarction, UA unstable angina
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of obesity and T2DM indicates that empagliflozin may 
improve CV injury and remodelling, vascular dysfunction, 
and cognitive decline [66]; in addition to reducing arterial 
stiffness in young patients with T1DM [67].
In line with this multifactorial risk factor hypothesis, 
and results generated from this and other meta-analyses 
that investigated the effects of SGLT2 inhibitors on CV 
outcomes, positive results were also recently reported 
with empagliflozin, in the first CV outcomes study with 
an SGLT2 inhibitor in patients with T2DM and estab-
lished CVD [47]. Superiority for the primary outcome of 
MACE was driven by significantly lower rates of death 
from CV causes while there was no statistical difference 
between the treatment groups in rates of MI or stroke. 
Significantly lower rates of hospitalisation for heart failure 
and death from any cause were also observed; consistent 
with the current analysis, which reported beneficial or 
neutral point estimates for all CV events with dapagliflo-
zin, including a beneficial estimate on hospitalisation for 
heart failure. It should be noted that eGFR levels were 
higher in the current study than the empagliflozin study 
[47] [baseline eGFR (SD): 83.9 (21.3) and 83.6 (21.1) mL/
min/1.73 m2 with dapagliflozin and control, respectively; 
vs. 74.2 (21.6) and 73.8 (21.1) mL/min/1.73 m2 with empa-
gliflozin and placebo], which could potentially impact on 
the overall frequency of CV events.
In the empagliflozin CV outcomes study, the cumula-
tive probability of the primary outcome showed an early 
separation between the treatment groups [47]. In the cur-
rent meta-analysis, a gradual separation was seen between 
the dapagliflozin and control curves, based on 134 MACE 













































1.009 (0.491, 2.074) 
HR (95% CI)
0.785 (0.365, 1.689) 
0.578 (0.301, 1.107) 
0.883 (0.442, 1.767) 
0.795 (0.512, 1.233) 
0.371 (0.155, 0.889) 
0.806 (0.317, 2.050) 
1.018 (0.369, 2.811) 
0.767 (0.295, 1.994) 
Elderly patients with CVD history and hypertension
8/676 9/531 Unstable angina
20/693 18/545 Unplanned coronary revascularisation
0.96 
2.39 
5/608 6/505 Hospitalisation for heart failure 0.67 
0.706 (0.263, 1.895) 
0.952 (0.493, 1.836) 






















10/2576 16/1780 Hospitalisation for heart failure 0.15 0.41 
Overall
0.999 (0.536, 1.864) 
0.704 (0.364 , 1.359) 
0.567 (0.339, 0.947) 
0.870 (0.475, 1.593) 
0.729 (0.497, 1.067) 
0.361 (0.156, 0.838) 
Myocardial infarction 
Fig. 3 CV events. Data presented for the overall population, the subgroup of patients with a history of CVD (CVD history) and the subgroup of 
elderly patients aged ≥65 years with a history of CVD and hypertension (Elderly patients with CVD risk). n is the number of patients with an event; 
N is number of patients in treatment group. CI confidence interval, CTRL control, CV cardiovascular, CVD CV disease, DAPA dapagliflozin, HR hazard 
ratio, p–y = patient years
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Fig. 5 MACE in the overall population by number of CV risk factors present. n is the number of patients with an event; N is the number of patients 
in treatment group. CI confidence interval, CTRL control, DAPA dapagliflozin, HR hazard ratio, MACE major adverse cardiovascular events (CV death, 
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Fig. 4 MACE in the overall population by presence or absence of CV risk factors. n is the number of patients with an event; N is the number of 
patients in treatment group. CHD coronary heart disease, CI confidence interval, CV cardiovascular, CTRL control, DAPA dapagliflozin, eGFR estimated 
glomerular filtration rate, HR hazard ratio, Hx history, MACE major adverse cardiovascular events (CV death, myocardial infarction and stroke), 
p–y = patient–years










































































Fig. 6 Risk of MACE in the subgroup of patients with a history of CVD. (CVD history). Data presented by a the different types of CVD in patient 
history, and b the number of CVD event types in patient history. n is the number of patients with an event; N is the number of patients in treatment 
group. Coronary = coronary artery disease (myocardial infarction, hospitalisation for unstable angina, coronary artery bypass graft, percutaneous 
coronary intervention or stable angina); cerebrovascular = cerebrovascular disease (carotid artery disease, carotid endarterectomy or stenting, 
stroke or transient ischaemic attack); peripheral = peripheral vascular disease (amputation, peripheral vascular disease or peripheral vascular sur‑
gery). CHF congestive heart failure, CI confidence interval, CTRL control, CV cardiovascular, CVD CV disease, DAPA dapagliflozin, HR hazard ratio, MACE 
major adverse cardiovascular events (CV death, myocardial infarction and stroke), n/a not available, p–y = patient–years
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observed in the current analysis and the empagliflozin out-
come study, due to substantial differences in study design 
and population. Dapagliflozin and empagliflozin have sim-
ilar profiles and no established mechanism suggests a dif-
ferent time to effect. Similar time to effect patterns were 
observed for dapagliflozin and empagliflozin for hospitali-
sation for heart failure, although as previously noted this 
was based on only 26 events in this meta-analysis.
The CV effects of SGLT2 inhibitors calls for further 
studies and confirmation. The prospective, randomised 
CV outcomes trial DECLARE TIMI-58 [48], with an esti-
mated enrolment of 17,150 patients and expected median 
follow-up of more than 4 years, will document the effects 
of dapagliflozin on CV outcomes in patients ≥40  years 
old with T2DM and established CVD or multiple CV 
risk factors [48]. This study is uniquely positioned by its 
broader patient population, including both established 
CVD and multiple risk factor patients, large sample size 
and long-term follow-up to provide further evidence on 
the effects of SGLT2 inhibitors on CV risk.
Conclusions
In this meta-analysis of data from across the dapagli-
flozin clinical development programme, including high 
CV risk patients, there was no evidence for increased 
risk of major adverse CV events with dapagliflozin. The 
results suggest the potential for a beneficial CV effect by 
dapagliflozin which is consistent with the multifacto-
rial benefits on CV risk factors associated with SGLT2 
inhibitors.
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Fig. 7 MACE by occurrence of hypoglycaemic event. Data presented for the overall population and the subgroup of patients with a history of CVD 
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